Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.14% ...

Cassava Sciences Inc. ($SAVA) saw its stock plummet over 80% pre-market on Monday following the failure of a pivotal Phase 3 ...

Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn ... Following this news, the price of Cassava's common ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $154.92 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Stock futures gained on Monday, kicking off a holiday-shortened week, with markets closed on Thursday for Thanksgiving and ...

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study ...

Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its ...

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cassava Sciences, Inc. (SAVA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...